Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalating Phase I, Healthy Subjects Study of Intravenous OPN‐305, a Humanized Anti‐TLR2 Antibody

Upregulation of Toll‐like receptor 2 (TLR2) plays a critical role in inflammation associated with ischemia/reperfusion–induced tissue damage. OPN‐305 is the first humanized IgG4 monoclonal antibody against TLR2 in development and is intended for the prevention of reperfusion injury following renal t...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Clinical pharmacology and therapeutics Ročník 94; číslo 5; s. 593 - 600
Hlavní autori:	Reilly, M, Miller, R M, Thomson, M H, Patris, V, Ryle, P, McLoughlin, L, Mutch, P, Gilboy, P, Miller, C, Broekema, M, Keogh, B, McCormack, W, Wetering de Rooij, J
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.11.2013
Predmet:	Adolescent Adult Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - immunology Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal - pharmacology Dose-Response Relationship, Immunologic Double-Blind Method Humans Infusions, Intravenous Interleukin-6 - antagonists & inhibitors Interleukin-6 - blood Leukocyte Count Male Middle Aged Toll-Like Receptor 2 - immunology Young Adult
ISSN:	0009-9236, 1532-6535, 1532-6535
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!